The estimated Net Worth of Arthur A Torres is at least $81.5 Tausend dollars as of 5 November 2021. Arthur Torres owns over 600 units of Caredx Inc stock worth over $81,453 and over the last 3 years Arthur sold CDNA stock worth over $0.
Arthur has made over 1 trades of the Caredx Inc stock since 2021, according to the Form 4 filled with the SEC. Most recently Arthur bought 600 units of CDNA stock worth $28,572 on 5 November 2021.
The largest trade Arthur's ever made was buying 600 units of Caredx Inc stock on 5 November 2021 worth over $28,572. On average, Arthur trades about 120 units every 0 days since 2021. As of 5 November 2021 Arthur still owns at least 2,855 units of Caredx Inc stock.
You can see the complete history of Arthur Torres stock trades at the bottom of the page.
Arthur's mailing address filed with the SEC is C/O CAREDX, INC., 8000 MARINA BOULEVARD, BRISBANE, CA, 94005.
Over the last 10 years, insiders at Caredx Inc have traded over $60,271,359 worth of Caredx Inc stock and bought 1,726,634 units worth $9,072,700 . The most active insiders traders include Group Holdings (Sbs) Adviso..., Neil Gagnon und Peter Maag. On average, Caredx Inc executives and independent directors trade stock every 17 days with the average trade being worth of $615,506. The most recent stock trade was executed by Alexander L Johnson on 20 August 2024, trading 61,023 units of CDNA stock currently worth $1,432,820.
caredx: transforming transplant patient care through novel surveillance management solutions caredx, inc. is dedicated to improving the lives of organ transplant patients through non-invasive diagnostics. by combining the latest advances in genomics and bioinformatics technology, with a commitment to generating high quality clinical evidence through trials and registries, caredx is at the forefront of organ transplant surveillance and pre-transplant hla typing solutions. nasdaq:cdna about allosure® allosure is the first and only non-invasive blood test that directly measures allograft injury and identifies the probability of active rejection to better manage kidney transplant patients. allosure is a clinical-grade, proprietary next-generation sequencing (ngs) based test to detect donor-derived cell-free dna (dd-cfdna) in order to identify organ injury in kidney transplant recipients. allosure is analytically validated as a sensitive, specific, and precise measurement of dd-cfdna. allos
Caredx Inc executives and other stock owners filed with the SEC include: